Another possible explanation is that the inflammatory cytokine involved in the occurrence of irAEs could modify the treatment efficiency in cancer patients, and the patients carrying genetic variations near the interleukin-7 (IL-7) gene may have both a higher incidence of irAEs and improved survival. This evidence concerns the gene IL7 and cancer.